Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1500 participants
OBSERVATIONAL
2022-10-03
2029-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard of Care Checkpoint
Patients receiving standard of care FDA approved immunotherapy
Methylation Cytometry
Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.
Bone Marrow Transplant
Patients undergoing transplant for hematologic malignancy
Methylation Cytometry
Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.
CAR T
Patients undergoing CAR T therapy
Methylation Cytometry
Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Methylation Cytometry
Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).
Exclusion Criteria
* Prisoners
* Decision-impaired individuals
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dartmouth-Hitchcock Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Brock C. Christensen
Professor of Epidemiology, Molecular and Systems Biology, and of Community and Family Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brock C Christensen, PhD
Role: PRINCIPAL_INVESTIGATOR
Dartmouth College
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Study02001227
Identifier Type: -
Identifier Source: org_study_id